KCG
VNDA icon

Knight Capital Group’s Vanda Pharmaceuticals VNDA Stock Holding History

Knight Capital Group’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q2 		$166K Buy
+20,559
New +$138K ﹤0.01% 2787

Other funds holding VNDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Knight Capital Group's VNDA Position: Q2 2013 in Review

Knight Capital Group opened a new position in Vanda Pharmaceuticals (VNDA) in Q2 2013: 20,559 shares worth $166K. The stake represents ﹤0.01% of the portfolio and ranks #2787 among its holdings.

88 funds tracked by Wall St. Rank hold VNDA as of Q2 2013.

  • Knight Capital Group held 20,559 shares of Vanda Pharmaceuticals worth $166K as of Q2 2013.
  • Vanda Pharmaceuticals was a new Knight Capital Group position in Q2 2013.
  • Vanda Pharmaceuticals made up ﹤0.01% of Knight Capital Group's portfolio in Q2 2013, its #2787 holding.
  • 88 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2013.

Based on Knight Capital Group's 13F filing for Q2 2013, filed 8 Aug 2013.